Aadi bioscience relaunches as whitehawk therapeutics marking evolution into adc company

New name reflects focus on accelerating portfolio of advanced adc therapies with speed, agility and precision upon closing of strategic transactions, cash expected to fund operations into 2028 enabling anticipated key clinical data readouts for its adc assets company shares to trade on nasdaq under the symbol "whwk" effective march 19, 2025 company reports financial results for the fourth quarter and full-year 2024, and will host a conference call tomorrow, march 19 at 8:30 am et morristown, n.j. , march 18, 2025 /prnewswire/ -- whitehawk therapeutics, inc. (nasdaq: whwk), formerly known as aadi bioscience, inc., an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today announced it changed its name to whitehawk therapeutics, reflecting the company's evolution and focus on accelerating its portfolio of antibody drug conjugates (adcs) with speed, agility and precision.
AADI Ratings Summary
AADI Quant Ranking